Dashboard
With a growth in Operating Profit of 55.51%, the company declared Very Positive results in Jun 25
- OPERATING CASH FLOW(Y) Highest at USD 305.61 MM
- RAW MATERIAL COST(Y) Fallen by 0.25% (YoY)
- NET SALES(Q) Highest at USD 811.09 MM
High Institutional Holdings at 100%
Market Beating performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
USD 10,202 Million (Small Cap)
NA (Loss Making)
NA
0.00%
0.61
-6.25%
4.13
Total Returns (Price + Dividend) 
EXACT Sciences Corp. for the last several years.
Risk Adjusted Returns v/s 
News

EXACT Sciences Corp. Experiences Revision in Stock Evaluation Amid Market Dynamics
EXACT Sciences Corp., a small-cap in the Pharmaceuticals & Biotechnology sector, has seen its stock price slightly decline recently. The company has experienced significant volatility over the past year. Technical indicators suggest a bullish sentiment, while its performance has varied compared to the S&P 500, showing resilience over longer periods.
Read More
EXACT Sciences Forms Golden Cross, Signaling Potential Bullish Breakout Ahead
EXACT Sciences Corp. has recently achieved a Golden Cross, signaling a potential shift in market momentum. Current technical indicators suggest a bullish outlook, with positive trends in moving averages and Bollinger Bands. Despite a challenging year, the stock has shown resilience with recent gains, reflecting improved market sentiment.
Read More
EXACT Sciences Corp. Experiences Revision in Stock Evaluation Amid Market Dynamics
EXACT Sciences Corp., a small-cap in the Pharmaceuticals & Biotechnology sector, has seen its stock price rise slightly to $57.63. The stock has experienced notable volatility over the past year, with mixed technical indicators suggesting varying market sentiments. Its performance has been inconsistent compared to the S&P 500.
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Domestic Funds
Held in 136 Schemes (59.56%)
Held by 345 Foreign Institutions (19.65%)
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
YoY Growth in quarter ended Jun 2025 is 15.99% vs 12.41% in Jun 2024
YoY Growth in quarter ended Jun 2025 is 92.41% vs 80.49% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is 10.36% vs 19.93% in Dec 2023
YoY Growth in year ended Dec 2024 is -404.12% vs 67.27% in Dec 2023






